文献速递肝病消化道肿瘤与早癌

非酒精性脂肪性肝病患者肝细胞癌发病率:系统综述、荟萃分析与荟萃回归

Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-05-28

该系统综述纳入18项研究、共470,404例NAFLD患者,采用随机效应模型汇总不同疾病严重阶段肝细胞癌(HCC)的发病率。非肝硬化阶段HCC发病率为0.03/100人年(95%CI 0.01-0.07),肝硬化阶段为3.78/100人年(95%CI 2.47-5.78),接受规律筛查的肝硬化患者为4.62/100人年(95%CI 2.77-7.72)。NAFLD相关肝硬化患者HCC风险与其他病因肝硬化相似。

要点

  • NAFLD肝硬化患者HCC发病率约3.78/100人年,与其他病因肝硬化相近
  • 非肝硬化NAFLD患者HCC发病率低至0.03/100人年,可能低于筛查推荐阈值
  • NAFLD相关肝硬化患者应纳入HCC监测体系

核心结论

  • NAFLD相关肝硬化患者发生HCC的风险与其他病因肝硬化患者相似。
  • 非酒精性脂肪性肝炎或单纯性脂肪变患者的HCC风险证据有限,发病率可能低于推荐筛查的阈值。

研究设计与样本

  • 系统综述与荟萃分析,检索Web of Science、Embase、PubMed和Cochrane Library(1950年1月1日至2020年7月30日)。
  • 纳入18项报告NAFLD患者HCC发病率的研究,共470,404例患者。
  • 采用随机效应模型汇总不同疾病严重阶段的HCC发病率,并进行敏感性分析和荟萃回归分析。
  • 方案注册于Prospero数据库(注册号CRD42018092861)。

主要发现

  • 非肝硬化阶段NAFLD患者HCC发病率为0.03/100人年(95%CI 0.01-0.07;I2=98%)。
  • 肝硬化阶段NAFLD患者HCC发病率为3.78/100人年(95%CI 2.47-5.78;I2=93%)。
  • 接受规律HCC筛查的肝硬化患者HCC发病率为4.62/100人年(95%CI 2.77-7.72;I2=77%)。

关键数值与推荐

  • 非肝硬化NAFLD:HCC发病率0.03/100人年(95%CI 0.01-0.07)。
  • NAFLD肝硬化:HCC发病率3.78/100人年(95%CI 2.47-5.78)。
  • NAFLD肝硬化接受规律筛查:HCC发病率4.62/100人年(95%CI 2.77-7.72)。

临床怎么用

  • NAFLD相关肝硬化患者应纳入HCC监测,其风险与其他病因肝硬化相当。
  • 非肝硬化NAFLD患者HCC风险较低,是否筛查需个体化评估。

局限性

  • 非酒精性脂肪性肝炎或单纯性脂肪变患者的HCC风险证据有限。
  • 各阶段发病率汇总存在显著异质性(I2最高达98%)。
  • 需在这些亚组人群中开展设计良好的前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) may be a risk factor for hepatocellular carcinoma (HCC), but the extent of this association still needs to be addressed. Pooled incidence rates of HCC across the disease spectrum of NAFLD have never been estimated by meta-analysis. METHODS: In this systematic review, we searched Web of Science, Embase, PubMed, and the Cochrane Library from January 1, 1950 through July 30, 2020. We included studies reporting on HCC incidence in patients with NAFLD. The main outcomes were pooled HCC incidences in patients with NAFLD at distinct severity stages. Summary estimates were calculated with random-effects models. Sensitivity analyses and meta-regression analyses were carried out to address heterogeneity. RESULTS: We included 18 studies involving 470,404 patients. In patients with NAFLD at a stage earlier than cirrhosis, the incidence rate of HCC was 0.03 per 100 person-years (95% confidence interval [CI], 0.01-0.07; I2 = 98%). In patients with cirrhosis, the incidence rate was 3.78 per 100 person-years (95% CI, 2.47-5.78; I2 = 93%). Patients with cirrhosis undergoing regular screening for HCC had an incidence rate of 4.62 per 100 person-years (95% CI, 2.77-7.72; I2 = 77%). CONCLUSIONS: Patients with NAFLD-related cirrhosis have a risk of developing HCC similar to that reported for patients with cirrhosis from other etiologies. Evidence documenting the risk in patients with nonalcoholic steatohepatitis or simple steatosis is limited, but the incidence of HCC in these populations may lie below thresholds used to recommend a screening. Well-designed prospective studies in these subpopulations are needed. The protocol for this systematic review is registered in the Prospero database (registration number CRD42018092861).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Orci LA, Sanduzzi-Zamparelli M, Caballol B, et al. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. Clin Gastroenterol Hepatol. 2021. PMID: 33965578. doi:10.1016/j.cgh.2021.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。